Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America’s most successful small-cap companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Company Ownership:
Public

Stock Symbol:
CPRX

Stock Exchange:
Nasdaq

355 Alhambra Circle, Suite 801
Coral Gables, FL 33134
  • 2025 BPTW Badge - RBG.png
NEWS
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
FDA
In the next two weeks, the FDA is scheduled to decide on four drug applications and hold two highly anticipated advisory committee meetings.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Resubmission of NDA for Firdapse on schedule for end of the first quarter.
JOBS
IN THE PRESS